Hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients receiving rituximab for lymphoma: a meta-analysis.

Abstract:

:Patients with chronic hepatitis B (HBsAg-positive) are at risk of viral reactivation if rituximab is administered without antiviral treatment, a potentially fatal complication of treatment. Patients with so-called 'resolved hepatitis B virus infection' (HBsAg-negative/cAb-positive) may also be at risk. We performed a systematic review of the English and Chinese language literature to estimate the risk of hepatitis B virus (HBV) reactivation in HBsAg-negative/cAb-positive patients receiving rituximab for lymphoma. A pooled risk estimate was calculated for HBV reactivation. The impact of HBsAb status and study design on reactivation rates was explored. Data from 578 patients in 15 studies were included. 'Clinical HBV reactivation', (ALT >3 × normal and either an increase in HBV DNA from baseline or HBsAg seroreversion), was estimated at 6.3% (I(2) = 63%, P = 0.006). Significant heterogeneity was detected. Reactivation rates were higher in prospective vs retrospective studies (14.2% vs 3.8%; OR = 4.39, 95% CI 0.83-23.28). Exploratory analyses found no effect of HBsAb status on reactivation risk (OR = 0.083; P = 0.151). Our meta-analysis confirms a measurable and potentially substantial risk of HBV reactivation in HBsAg-negative/cAb-positive patients exposed to rituximab. However, heterogeneity in the existing literature limits the generalizability of our findings. Large, prospective studies, with uniform definitions of HBV reactivation, are needed to clarify the risk of HBV reactivation in HBsAg-negative/cAb-positive patients.

journal_name

J Viral Hepat

authors

Mozessohn L,Chan KK,Feld JJ,Hicks LK

doi

10.1111/jvh.12402

subject

Has Abstract

pub_date

2015-10-01 00:00:00

pages

842-9

issue

10

eissn

1352-0504

issn

1365-2893

journal_volume

22

pub_type

杂志文章,meta分析,评审
  • Elimination of hepatitis B virus surface antigen and appearance of neutralizing antibodies in chronically infected patients without viral clearance.

    abstract::Seroconversion from hepatitis B surface antigen (HBsAg) to antibodies against HBsAg (anti-HBs) usually indicates resolution of hepatitis B virus (HBV) infection. Here, two HBV-infected patients with seroconversion to anti-HBs were found to be persistently positive for HBeAg and HBV DNA. Immunohistology of liver biopsi...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2010.01322.x

    authors: Zhang ZH,Li L,Zhao XP,Glebe D,Bremer CM,Zhang ZM,Tian YJ,Wang BJ,Yang Y,Gerlich W,Roggendorf M,Li X,Lu M,Yang DL

    更新日期:2011-06-01 00:00:00

  • Different responses of rat liver adenosine metabolizing enzymes during in vivo and in vitro treatment with interferon-alpha 2b.

    abstract::Interferon-alpha 2b (IFN-alpha 2b) can exert antiproliferative activity in both normal and malignant liver tissue. To study mechanisms of its antiproliferative action, the activity of the enzymes of adenosine metabolism were investigated. We studied 5'-nucleotidase (an adenosine-producing enzyme) and adenosine deamina...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1046/j.1365-2893.1998.00117.x

    authors: Kocić G,Kocić R,Vlahović P,Pavlović D,Jevtović T

    更新日期:1998-09-01 00:00:00

  • Access to therapy and therapy outcomes in the Swiss Hepatitis C Cohort Study: a person-centred approach.

    abstract::Socio-demographic and behavioural characteristics are associated with delayed diagnosis and disease progression in HCV-infected persons. However, many analyses focused on single variables rather than groups defined by several variables. We used latent class analysis to study all 4488 persons enrolled in the Swiss Hepa...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12535

    authors: Giudici F,Bertisch B,Negro F,Stirnimann G,Müllhaupt B,Moradpour D,Cerny A,Keiser O,Swiss Hepatitis C Cohort Study.

    更新日期:2016-09-01 00:00:00

  • Awareness of chronic viral hepatitis in the United States: An update from the National Health and Nutrition Examination Survey.

    abstract::The World Health Organization has set the goal of reducing the hepatitis-related mortality rate by 65% between 2015 and 2030. Diagnosis and awareness of infection is the first essential step towards achieving this goal. Our study examined the current awareness rate of chronic viral hepatitis in the United States and t...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.13060

    authors: Kim HS,Yang JD,El-Serag HB,Kanwal F

    更新日期:2019-05-01 00:00:00

  • TyG index, HOMA score and viral load in patients with chronic hepatitis C due to genotype 1.

    abstract::The triglycerides × glucose (TyG) index is a recently proposed surrogate marker of insulin resistance (IR), calculated from fasting plasma triglyceride and glucose concentrations. We tested the host and viral factors associated with Tyg and homeostasis model assessment (HOMA) scores, comparing their associations with ...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2011.01439.x

    authors: Petta S,Di Marco V,Di Stefano R,Cabibi D,Cammà C,Marchesini G,Craxì A

    更新日期:2011-07-01 00:00:00

  • Safety and immunogenicity of HBAI20 Hepatitis B vaccine in healthy naïve and nonresponding adults.

    abstract::Approximately 5% of the healthy adult population respond inadequately to the commercial recombinant hepatitis B vaccines. As the recombinant vaccines all have an aluminium-based adjuvant, we tried to enhance the immune response by adding a cytokine-based adjuvant. This new adjuvant AI20, containing 20 μg recombinant h...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,随机对照试验

    doi:10.1111/jvh.12909

    authors: Koc ÖM,Savelkoul PHM,van Loo IHM,Peeters A,Oude Lashof AML

    更新日期:2018-09-01 00:00:00

  • In vivo immunization in combination with peg-interferon for chronic hepatitis B virus infection.

    abstract::Only in a minority of patients with chronic hepatitis B (CHB) will treatment with interferon (IFN)-alpha or nucleoside analogues lead to sustained virological response. In vivo immunization (IVI) following virus suppression aims to optimize conditions for an effective immune response: following rapid and profound viru...

    journal_title:Journal of viral hepatitis

    pub_type: 临床试验,杂志文章

    doi:10.1111/j.1365-2893.2007.00841.x

    authors: Sprengers D,van der Molen RG,Binda R,Kusters JG,de Man RA,Niesters HG,Schalm SW,Janssen HL

    更新日期:2007-10-01 00:00:00

  • Altered balance between collagen formation and degradation after successful direct-acting antiviral therapy of chronic hepatitis C.

    abstract::The effect of direct-acting antiviral (DAA) therapy on extracellular matrix (ECM) turnover, a prominent feature of chronic hepatitis C (CHC), is unknown. ECM protein degradation and formation generate fragments reflecting the tissue turnover balance when quantified in the blood. PRO-C3 and PRO-C4 reflect type III and ...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.13416

    authors: Laursen TL,Villesen IF,Leeming DJ,Karsdal MA,Sølund C,Tarp B,Kristensen LH,Holmboe CH,Leutscher P,Laursen AL,Gudmann NS,Grønbaek H

    更新日期:2021-02-01 00:00:00

  • Incidence and clinical significance of hepatitis B virus precore gene translation initiation mutations in e antigen-negative patients.

    abstract::Hepatitis Be antigen (HBeAg)-negative chronic hepatitis B (CHB) is associated with hepatitis B virus (HBV) variants harbouring changes in the precore region. Most commonly, a G to A point mutation at nucleotide 1896 (m1896) creates a novel translation stop codon that prevents HBeAg production. In the Mediterranean reg...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1046/j.1365-2893.1998.00109.x

    authors: Laras A,Koskinas J,Avgidis K,Hadziyannis SJ

    更新日期:1998-07-01 00:00:00

  • Preclinical aspects of lamivudine and famciclovir against hepatitis B virus.

    abstract::Chemotherapy for chronic hepatitis B virus (HBV) infection is inherently difficult for a variety of reasons that are related to unusual features of both HBV replication strategy and host cell metabolism. Previous attempts to treat chronic HBV infection using nucleoside analogues have been almost universally disappoint...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,评审

    doi:10.1046/j.1365-2893.1999.00151.x

    authors: Shaw T,Locarnini SA

    更新日期:1999-03-01 00:00:00

  • Quantitative evaluation of cytomegalovirus DNA in infantile hepatitis.

    abstract::We used a PCR method to develop a diagnostic assay for the detection of cytomegalovirus (CMV) DNA in infantile hepatitis, which has been suggested to be associated with CMV infection. CMV DNA was detected in 25 (58.1%) of 43 patients with elevated serum alanine aminotransferase (ALT) levels but no jaundice, and no hep...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1046/j.1365-2893.2001.00277.x

    authors: Funato T,Satou N,Abukawa D,Satou J,Abe Y,Ishii KK,Iinuma K,Kaku M,Sasaski T

    更新日期:2001-05-01 00:00:00

  • Hypervariable region 1 quasispecies in hepatitis C virus genotypes 1b and 3 infected patients with normal and abnormal alanine aminotransferase levels.

    abstract::The role of hepatitis C virus (HCV) heterogeneity in the severity of chronic hepatitis C infection remains unclear. Our aim was to study the hypervariable region 1 (HVR1) heterogeneity in patients with chronic hepatitis C infected with genotype 1b or 3 and with normal or abnormal alanine aminotransferase (ALT). HVR1 q...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1046/j.1365-2893.2002.00327.x

    authors: Asselah T,Martinot M,Cazals-Hatem D,Boyer N,Auperin A,Le Breton V,Erlinger S,Degott C,Valla D,Marcellin P

    更新日期:2002-01-01 00:00:00

  • Interferon-alpha plus amantadine in chronic hepatitis C resistant to interferon alone: a pilot randomized study.

    abstract::The optimal therapy for patients with chronic hepatitis C who have not responded to interferon (IFN) is still an unsolved issue. The aim of this study was to evaluate the efficacy and tolerability of a high dose of IFN-alpha2a plus amantadine for chronic hepatitis C patients who were non-responders to a previous cours...

    journal_title:Journal of viral hepatitis

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1046/j.1365-2893.2001.00298.x

    authors: Gaeta GB,Stornaiuolo G,Stanzione M,Ascione T,Pasquazzi C,Taliani G,Cimino L,Budillon G,Piccinino F

    更新日期:2001-07-01 00:00:00

  • Effectiveness of triple therapy with simeprevir for chronic hepatitis C genotype 1b patients with prior telaprevir failure.

    abstract::Favourable efficacy and safety profiles for simeprevir in combination with pegylated interferon alpha (PEG-IFNα) and ribavirin (triple therapy) have been shown in clinical trials. This study was carried out to evaluate the effectiveness of simeprevir-based triple therapy for patients with prior telaprevir treatment fa...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,多中心研究

    doi:10.1111/jvh.12427

    authors: Ogawa E,Furusyo N,Dohmen K,Kajiwara E,Kawano A,Nomura H,Takahashi K,Satoh T,Azuma K,Nakamuta M,Koyanagi T,Kotoh K,Shimoda S,Hayashi J,Kyushu University Liver Disease Study (KULDS) Group.

    更新日期:2015-12-01 00:00:00

  • Drug use and phylogenetic clustering of hepatitis C virus infection among people who use drugs in Vancouver, Canada: A latent class analysis approach.

    abstract::This study estimated latent classes (ie, unobserved subgroups in a population) of people who use drugs in Vancouver, Canada, and examined how these classes relate to phylogenetic clustering of hepatitis C virus (HCV) infection. HCV antibody-positive people who use drugs from two cohorts in Vancouver, Canada (1996-2012...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12758

    authors: Jacka B,Bray BC,Applegate TL,Marshall BDL,Lima VD,Hayashi K,DeBeck K,Raghwani J,Harrigan PR,Krajden M,Montaner JSG,Grebely J Senior

    更新日期:2018-01-01 00:00:00

  • Efficacy and tolerance of a 6-month treatment course of daily interferon-alpha 2a for chronic hepatitis C with cirrhosis. The Australian Hepatitis C Study Group.

    abstract::Response to interferon-alpha (IFN-alpha) treatment in hepatitis C is poorer when cirrhosis is present. In the third Australian multicentre hepatitis C trial, Aushep-3, we examined the efficacy and tolerability of an intensive 24-week course of interferon-alpha 2a in Child-Pugh grade A patients with chronic hepatitis C...

    journal_title:Journal of viral hepatitis

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1046/j.1365-2893.1997.00062.x

    authors: Farrell G,Cooksley WG,Dudley FJ,Watson K

    更新日期:1997-09-01 00:00:00

  • The impact of currently licensed therapies on viral and immune responses in chronic hepatitis B: Considerations for future novel therapeutics.

    abstract::Despite the availability of a preventative vaccine, chronic hepatitis B (CHB) remains a global healthcare challenge with the risk of disease progression due to cirrhosis and hepatocellular carcinoma. Although current treatment strategies, interferon and nucleos(t)ide analogues have contributed to reducing morbidity an...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,评审

    doi:10.1111/jvh.13040

    authors: Gill US,Kennedy PTF

    更新日期:2019-01-01 00:00:00

  • Susceptibility to active decompensated cirrhosis is associated with polymorphisms of intercellular adhesion molecule-1 (ICAM-1) in chronic HBV carriers.

    abstract::Intercellular adhesion molecule-1 (ICAM-1) plays an important role in the pathogenesis of viral hepatitis B. Several inflammatory diseases are associated with distinct polymorphisms of the ICAM-1 gene. The aims of this study were to analyse the association of ICAM-1 polymorphisms G241R and K469E with susceptibility to...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2007.00931.x

    authors: Zhang XQ,Hong XJ,Bai XJ

    更新日期:2008-03-01 00:00:00

  • Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States.

    abstract::The aim of this work was to estimate the future disease burden of hepatitis C virus (HCV) and human immunodeficiency virus (HIV) infections in the United States until the year 2030. Two back-calculation models of the HIV and the HCV epidemic were developed. They were based on US epidemiological data regarding prevalen...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2006.00785.x

    authors: Deuffic-Burban S,Poynard T,Sulkowski MS,Wong JB

    更新日期:2007-02-01 00:00:00

  • Delayed viral suppression during antiviral therapy is associated with increased hepatocellular carcinoma rates in HBeAg-positive high viral load chronic hepatitis B.

    abstract::The treatment option in chronic hepatitis B (CHB) patients with persistent low-level viremia despite entecavir or tenofovir monotherapy is unclear. This study investigated the development of hepatocellular carcinoma (HCC) or cirrhosis in hepatitis B e antigen (HBeAg)-positive high viral load CHB patients, according to...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12838

    authors: Nam JY,Chang Y,Cho H,Kang SH,Cho YY,Cho EJ,Lee JH,Yu SJ,Yoon JH,Kim YJ

    更新日期:2018-05-01 00:00:00

  • Prevalence of HBsAg/HBeAg amongst 1 936 801 couples preparing for pregnancy in rural China: An observational study.

    abstract::There are few extant studies on the prevalence of HBV infection in couples preparing for pregnancy. We assessed the prevalence of hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) in couples preparing for pregnancy in rural China, and the association between HBV prevalence and the statuses of HBsAg...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12693

    authors: Liu J,Zhang S,Wang Q,Shen H,Zhang M,Zhang Y,Yan D,Liu M

    更新日期:2017-08-01 00:00:00

  • Activity of adefovir dipivoxil against all patterns of lamivudine-resistant hepatitis B viruses in patients.

    abstract::One hundred and thirty-one post-liver transplantation patients with chronic hepatitis B and failing lamivudine therapy with detectable serum hepatitis B virus (HBV) deoxyribonucleic acid by hybridization assays or > or =1 x 10(6) copies/mL by polymerase chain reaction, and elevated alanine transaminase levels despite ...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2005.00578.x

    authors: Westland CE,Yang H,Delaney WE 4th,Wulfsohn M,Lama N,Gibbs CS,Miller MD,Fry J,Brosgart CL,Schiff ER,Xiong S

    更新日期:2005-01-01 00:00:00

  • A possible role of hypervariable region 1 quasispecies in escape of hepatitis C virus particles from neutralization.

    abstract::We examined serial changes in the hypervariable region 1(HVR1) quasispecies both in immune and nonimmune complexed hepatitis C virus (HCV) particles from 12 patients with chronic hepatitis C to elucidate the mechanism by which genetic diversification of HCV during the course of infection allows escape of virus from th...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1046/j.1365-2893.2001.00305.x

    authors: Korenaga M,Hino K,Katoh Y,Yamaguchi Y,Okuda M,Yoshioka K,Okita K

    更新日期:2001-09-01 00:00:00

  • Decline in intrahepatic cccDNA and increase in immune cell reactivity after 12 weeks of antiviral treatment were associated with HBeAg loss.

    abstract::Viral load reduction facilitates recovery of antiviral T-cell responses. Dynamic alterations in intrahepatic viraemia clearance and immune cell reactivity during the early phase of nucleoside analogue (NA) therapy and the impact of these changes on HBeAg seroconversion are unknown. Fifteen HBeAg-positive chronic hepat...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12261

    authors: Zheng Q,Zhu YY,Chen J,Liu YR,You J,Dong J,Zeng DW,Gao LY,Chen LH,Jiang JJ

    更新日期:2014-12-01 00:00:00

  • Autoantibodies in chronic hepatitis C virus infection and their association with disease profile.

    abstract::Autoantibodies are commonly detected in chronic hepatitis C (HCV) but their significance remains uncertain. We assessed the prevalence of anti-nuclear (ANA) and anti-smooth muscle (ASM) antibodies within a cohort of 963 treatment-naïve HCV patients. We also assessed for differences between autoantibody-positive and au...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2008.01035.x

    authors: Williams MJ,Lawson A,Neal KR,Ryder SD,Irving WL,Trent HCV Group.

    更新日期:2009-05-01 00:00:00

  • GS-9857 in patients with chronic hepatitis C virus genotype 1-4 infection: a randomized, double-blind, dose-ranging phase 1 study.

    abstract::GS-9857, an inhibitor of the hepatitis C virus (HCV) nonstructural protein (NS) 3/4A, demonstrates potent activity against HCV genotypes 1-6 and improved coverage against commonly encountered NS3 resistance-associated variants (RAVs). In this study, the safety, tolerability, antiviral activity and pharmacokinetics (PK...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1111/jvh.12527

    authors: Rodriguez-Torres M,Glass S,Hill J,Freilich B,Hassman D,Di Bisceglie AM,Taylor JG,Kirby BJ,Dvory-Sobol H,Yang JC,An D,Stamm LM,Brainard DM,Kim S,Krefetz D,Smith W,Marbury T,Lawitz E

    更新日期:2016-08-01 00:00:00

  • Disparity of basal and therapeutically activated interferon signalling in constraining hepatitis E virus infection.

    abstract::Hepatitis E virus (HEV) represents one of the foremost causes of acute hepatitis globally. Although there is no proven medication for hepatitis E, pegylated interferon-α (IFN-α) has been used as off-label drug for treating HEV. However, the efficacy and molecular mechanisms of how IFN signalling interacts with HEV rem...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12491

    authors: Zhou X,Xu L,Wang W,Watashi K,Wang Y,Sprengers D,de Ruiter PE,van der Laan LJ,Metselaar HJ,Kamar N,Peppelenbosch MP,Pan Q

    更新日期:2016-04-01 00:00:00

  • Immune modulation by the hepatitis C virus core protein.

    abstract::Hepatitis C virus (HCV) infection is currently the most important cause of chronic viral hepatitis in the world and one of the most frequent indications for liver transplantation. HCV uses different strategies to evade the innate and adaptive immune response, and this evasion plays a key role in determining viral pers...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,评审

    doi:10.1111/jvh.12675

    authors: Fernández-Ponce C,Dominguez-Villar M,Muñoz-Miranda JP,Arbulo-Echevarria MM,Litrán R,Aguado E,García-Cozar F

    更新日期:2017-05-01 00:00:00

  • Retreatment for 24 vs 48 weeks with interferon-alpha2b plus ribavirin of chronic hepatitis C patients who relapsed or did not respond to interferon alone.

    abstract::We assessed the efficacy of interferon (IFN) plus ribavirin over 24 or 48 weeks for the retreatment of patients with chronic hepatitis C who had relapsed or did not respond to a previous course of IFN. One-hundred and twenty patients (69 non-responders and 51 relapsers) were randomly assigned to receive IFN-alpha2b (3...

    journal_title:Journal of viral hepatitis

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1046/j.1365-2893.2000.00243.x

    authors: Enríquez J,Gallego A,Torras X,Pérez-Olmeda T,Diago M,Soriano V,Luján MS,García-Samaniego J

    更新日期:2000-11-01 00:00:00

  • Renal function during treatment with adefovir plus peginterferon alfa-2a vs either drug alone in hepatitis B/D co-infection.

    abstract::Long-term safety of treatment with hepatitis B virus (HBV) polymerase inhibitors is a concern. Adefovir dipivoxil (ADV) therapy has previously been associated with impairment of renal function. Limited data are available on the safety of combination therapy with nucleos(t)ide analogues and interferon alfa (IFNα). The ...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1111/j.1365-2893.2011.01560.x

    authors: Mederacke I,Yurdaydin C,Großhennig A,Erhardt A,Cakaloglu Y,Yalcin K,Gurel S,Zeuzem S,Zachou K,Chatzikyrkou C,Bozkaya H,Dalekos GN,Manns MP,Wedemeyer H,Hep-Net\/International Delta Hepatitis Study Group.

    更新日期:2012-06-01 00:00:00